Only TTFields therapy harnesses the versatile power of electric fields to outsmart solid tumors and kill cancer cells1,2
IN YOUR FIGHT AGAINST CANCER, MAKE YOUR NEXT MOVE ELECTRIC
With a poor survival outlook, physicians and patients need additional solid tumor treatment strategies that utilize innovative modalities.1-3
Discover the innovation of TTFields therapyWhat is TTfields therapy?
TTFields therapy is clinically versatile, rooted in its multifaceted effect on cancer cells.4-6
Explore how its multiple mechanisms each work to disrupt tumor progression and kill cancer cells1,2How does it work?
TTFields have been extensively researched, with preclinical data demonstrating enhanced effects when used with other cancer treatments.4, 7-12
See its many potential applicationsSee the possibilities
As a cutting-edge technology, TTFields are the subject of ongoing investigations in multiple tumor types.7-12
Learn how you can educate colleagues on TTFields therapy with our specially designed slide kit as well as educational videos.EXPLORE RESOURCES
References: 1. Giladi M, Schneiderman RS, Voloshin T, et al. Mitotic spindle disruption by alternating electric fields leads to improper chromosome segregation and mitotic catastrophe in cancer cells. Sci Rep. 2015;5:1-16. doi:10.1038/srep18046 2. Kirson ED, Dbalý V, Tovaryš F, et al. Alternating electric fields arrest cell proliferation in animal tumor models and human brain tumors. Proc Natl Acad Sci U S A. 2007;104(24):10152-10157. doi:10.1073/pnas.0702916104 3. Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15(2):81-94. doi:10.1038/nrclinonc.2017.166 4. Gotwals P, Cameron S, Cipolletta D, et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat Rev Cancer. 2017;17(5):286-301. doi:10.1038/nrc.2017.17 5. Lopez JS, Banerji U. Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol. 2017;14(1):57-66. doi:10.1038/nrclinonc.2016.96 6. Karanam NK, Story MD. An overview of potential novel mechanisms of action underlying tumor treating fields-induced cancer cell death and their clinical implications. Int J Radiat Biol 2021;97(8):1044-1054. doi:10.1080/09553002.2020.1837984 7. Voloshin T, Schneiderman RS, Volodin A, et al. Tumor treating fields (TTFields) hinder cancer cell motility through regulation of microtubule and actin dynamics. Cancers (Basel). 2020;12(10):1-18. doi:10.3390/cancers12103016 8. Hall A. The cytoskeleton and cancer. Cancer Metastasis Rev. 2009;28(1-2):5-14. doi:10.1007/s10555-008-9166-3 9. Pless M, Droege C, von Moos R, Salzberg M, Betticher D. A phase I/II trial of tumor treating fields (TTFields) therapy in combination with pemetrexed for advanced non-small cell lung cancer. Lung Cancer. 2013;81(3):445-450. doi:10.1016/j.lungcan.2013.06.025 10. Novocure. Pivotal, open-label, randomized study of radiosurgery with or without tumor treating fields (TTFields) for 1-10 brain metastases from non-small cell lung cancer (NSCLC). Clinical Trials. Accessed June 21, 2022. https://clinicaltrials.gov/ct2/show/NCT02831959 11. Rivera F, Benavides M, Gallego J, Guillen-Ponce C, Lopez-Martin J, Küng M. Tumor treating fields in combination with gemcitabine or gemcitabine plus nab-paclitaxel in pancreatic cancer: results of the PANOVA phase 2 study. Pancreatology. 2019;19(1):64-72. doi:10.1016/j.pan.2018.10.004 12. Novocure. Effect of tumor treating fields (TTFields, 150 kHz) as front-line treatment of locally-advanced pancreatic adenocarcinoma concomitant with gemcitabine and nab-paclitaxel (PANOVA-3). Clinical Trials. Accessed June 21, 2022. https://clinicaltrials.gov/ct2/show/NCT03377491 13. Vergote I, von Moos R, Manso L, Van Nieuwenhuysen E, Concin N, Sessa C. Tumor treating fields in combination with paclitaxel in recurrent ovarian carcinoma: results of the INNOVATE pilot study. Gynecol Oncol. 2018;150(3):471-477. doi:10.1016/j.ygyno.2018.07.018 14. Novocure. Effect of tumor treating fields (TTFields, 200 kHz) concomitant with weekly paclitaxel for the treatment of recurrent ovarian cancer (ENGOT-ov50 / GOG-3029 / INNOVATE-3). Clinical Trials. Accessed June 21, 2022. https://clinicaltrials.gov/ct2/show/NCT03940196